Document Detail

Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavirin therapy?
MedLine Citation:
PMID:  19070444     Owner:  NLM     Status:  MEDLINE    
The great majority of patients with chronic viral hepatitis C are treated with pegylated interferon-ribavirin therapy. The aim of this study was to demonstrate that these patients were able to have some form of physical exercise, and that this activity can lead to an improvement in their quality-of-life. Twelve volunteer patients with hepatitis C, who were either sedentary or had become sedentary and who had been treated by combination therapy for the past few weeks, were recruited at hepatology clinics in the Midi-Pyrénées region of France early in 2006. All patients attended a sports medicine consultation for an initial evaluation: maximal aerobic power and maximal oxygen consumption tests, maximum heart rate (MHR), search for contraindications for participation in the proposed program of physical exercise. The patients were given a heart rate monitor so they could measure their heart rate during physical exercise and check that they exercised under safe conditions and remained within the so-called "endurance" zone. The patients came to a sports facility daily for 5 days for the exercise program. The activities were divided into four sessions each day: an individual physical exercise selected by the patient, team physical exercise, recreational physical exercise, lectures on the different types of hepatitis and their treatment, on nutrition and on sports medicine assessments. Data on hepatitis, results of the cardiorespiratory examination and personal history and record of past physical activity were collected for each patient. Quality-of-life (SF36) was assessed at enrollment in the study and one month after the training sessions. At the initial sports medicine consultation, all patients reached their MHR and were found capable of participating in the proposed physical exercise program. One enrolled patient was excluded from the analysis because of the presence of sinusitis on arrival. Seven men and four women, mean age of 46 years completed the full course of the study protocol. All participated in the three types of proposed physical activity with no problem. The score of the general perception item of the SF36 questionnaire increased from 63 on day 0 to 71 at one month (p=0.07). In conclusion, patients with hepatitis C receiving pegylated interferon plus ribavirin may safely participate in a program of suitably supervised physical exercise. Taking part in physical exercise leads to clear changes in the way patients perceive their bodies and its capacities. Participating in sports activities could improve self-confidence and lead to far-reaching changes in the way patients perceive their disease and the constraints of treatment.
J-L Payen; F Pillard; V Mascarell; D Rivière; P Couzigou; N Kharlov
Related Documents :
8300274 - Brief physical inactivity prolongs colonic transit time in elderly active men.
24970854 - Pulmonary gas exchange efficiency during exercise breathing normoxic and hypoxic gas in...
9745624 - Physical fitness: how to help older patients live stronger and longer. (1).
18059594 - Revised clearance for participation in physical activity: greater screening responsibil...
11404274 - Lactate-transport activity in rbcs of trained and untrained individuals from four racin...
8660684 - Antioxidants, tissue damage, and endurance in trained and untrained young male rats.
Publication Detail:
Type:  Journal Article     Date:  2008-12-12
Journal Detail:
Title:  Gastroentérologie clinique et biologique     Volume:  33     ISSN:  2210-7401     ISO Abbreviation:  Gastroenterol. Clin. Biol.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-22     Completed Date:  2009-05-11     Revised Date:  2010-08-17    
Medline Journal Info:
Nlm Unique ID:  7704825     Medline TA:  Gastroenterol Clin Biol     Country:  France    
Other Details:
Languages:  eng     Pagination:  8-14     Citation Subset:  IM    
Pôle médicochirurgical viscéral, centre hospitalier de Montauban, BP 765, 82013 Montauban cedex, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / therapeutic use
Drug Therapy, Combination
Hepatitis C, Chronic / drug therapy*
Interferon Alfa-2a / therapeutic use
Interferon Alfa-2b / therapeutic use
Middle Aged
Pilot Projects
Polyethylene Glycols / therapeutic use
Quality of Life*
Ribavirin / therapeutic use
Reg. No./Substance:
0/Antiviral Agents; 0/Polyethylene Glycols; 0/peginterferon alfa-2a; 0/peginterferon alfa-2b; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mercury fatal intoxication: Two case reports.
Next Document:  Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breas...